FANCA

FA complementation group A

Explore in graph →CI-GENE-00001605HGNC:3582 ENSG00000187741 NCBI 2175 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FANCA S1088F1
Cisplatin	Malignant Prostate Neoplasm	Predictive	C	Supports Sensitivity Response	4	submitted	EID5813 A patient with prostate cancer with exceptional response to treatment was identified who harbored a somatic hemizygous deletion of the DNA repair gene FANCA and putative partial loss of function of th… (full text at CIViC) PMID 26181256 · Beltran et al., 2015 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (115)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved115 cohort rows (showing 15, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Prostate Cancer (MSK, Clin Cancer Res 2024) prostate_msk_2024	unmapped	Ssm	15	2,260

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.